ISC1 Antibody

What is ISCA1/Isc1p and what are their functions in cellular biology?

ISCA1 (Iron-Sulfur Cluster Assembly 1) is a mitochondrial protein involved in the maturation of 4Fe-4S proteins, functioning late in the iron-sulfur cluster assembly pathway. In humans, this protein consists of 129 amino acid residues with a molecular mass of 14.2 kDa. ISCA1 is notably expressed in cerebellum, kidney, and heart tissue, and belongs to the HesB/IscA protein family. The ISCA1 gene has been associated with multiple mitochondrial dysfunctions syndrome, highlighting its clinical significance .

In contrast, Isc1p (inositolsphingolipid phospholipase C) in yeast is a homolog of mammalian neutral sphingomyelinases that hydrolyzes complex sphingolipids to produce ceramide. Isc1p localizes to the outer mitochondrial membrane as an integral membrane protein, particularly during the post-diauxic phase of yeast growth. This enzyme plays a critical role in sphingolipid metabolism and contributes to normal mitochondrial function .

What detection techniques are most effective for ISCA1/Isc1p research?

For ISCA1 detection and characterization, researchers commonly employ:

• ELISA (Enzyme-Linked Immunosorbent Assay): Provides quantitative detection with high sensitivity

• Western Blot: Allows size verification and semi-quantitative analysis of protein expression

• Immunofluorescence: Enables visualization of subcellular localization within intact cells

For Isc1p research in yeast models:

• Enzymatic activity assays: Measure Isc1p-specific activity in cellular fractions

• Western blotting with epitope-tagged constructs: Determine subcellular localization

• Protease protection assays: Analyze membrane topology

• LC/MS (Liquid Chromatography/Mass Spectrometry): Analyze sphingolipid composition in mitochondria

How should researchers verify antibody specificity for ISCA1/Isc1p?

Verification of antibody specificity is crucial for reliable research outcomes. Recommended approaches include:

• Genetic validation using knockout/knockdown models (e.g., isc1Δ yeast strain shows only background activity in enzymatic assays)

• Multiple antibody approach using different antibodies targeting distinct epitopes

• Recombinant protein controls as positive controls in immunodetection methods

• Preabsorption controls to block specific binding sites

• Cross-reactivity testing against related proteins

• Western blot analysis to confirm detection of a single band of expected molecular weight

• Mass spectrometry validation of immunoprecipitated proteins

How can researchers differentiate between different isoforms of ISCA1?

ISCA1 has up to two different reported isoforms in humans . Researchers can differentiate between these isoforms through:

• Isoform-specific antibodies: Design or select antibodies targeting unique regions of each isoform

• RT-PCR analysis: Design primers that specifically amplify each isoform

• Mass spectrometry: Identify isoform-specific peptides in tryptic digests

• 2D gel electrophoresis: Separate isoforms based on both molecular weight and isoelectric point

• Recombinant expression systems: Express individual isoforms as controls

What methodologies can effectively measure changes in ISCA1/Isc1p activity in disease models?

For measuring ISCA1 activity in disease models:

• Cluster transfer assays: Measure the transfer of iron-sulfur clusters to recipient proteins

• Mitochondrial function assays: Assess respiratory chain complex activities that depend on iron-sulfur clusters

• Protein-protein interaction studies: Analyze interactions with other components of the iron-sulfur cluster assembly machinery

• Metabolomic profiling: Identify changes in metabolites associated with iron-sulfur cluster deficiency

For measuring Isc1p activity:

• Sphingolipid hydrolysis assays: Quantify the enzymatic activity using labeled substrates

• LC/MS analysis: Measure specific ceramide species in mitochondria from wild-type versus disease models

• Mitochondrial stress tests: Compare respiratory capacity and response to oxidative stress

• Growth phenotype analysis: Assess growth in media containing non-fermentable carbon sources

Research has demonstrated that Isc1p-deficient yeast (isc1Δ) exhibits higher rates of respiratory-deficient cells after heat stress and increased sensitivity to hydrogen peroxide and ethidium bromide, indicating impaired mitochondrial function .

What are the optimal approaches for studying ISCA1/Isc1p interactions with mitochondrial membranes?

For studying ISCA1/Isc1p membrane interactions:

• Membrane fractionation:

  • Differential centrifugation to isolate mitochondria

  • Nycodenz gradient ultracentrifugation for high-purity mitochondria

  • Osmotic swelling to separate outer and inner mitochondrial membranes

• Topology determination:

  • Protease protection assays with and without membrane disruption

  • Selective permeabilization of membranes using digitonin

  • Antibodies against marker proteins (e.g., Cox3p, Porin, Mge1p) for different mitochondrial compartments

• Advanced microscopy:

  • Super-resolution microscopy for precise localization

  • FRAP (Fluorescence Recovery After Photobleaching) to study membrane dynamics

  • FRET to analyze protein-protein or protein-lipid interactions

• Biochemical characterization:

  • Alkaline extraction to distinguish peripheral from integral membrane proteins

  • Detergent solubility profiling to analyze membrane association

  • Blue native PAGE to identify membrane protein complexes

Research on Isc1p has successfully employed these approaches to demonstrate its localization to the outer mitochondrial membrane as an integral membrane protein .

What controls should be included in experiments using ISCA1/Isc1p antibodies?

A robust experimental design using ISCA1/Isc1p antibodies requires comprehensive controls:

• Negative controls:

  • Samples from knockout/knockdown models (e.g., isc1Δ yeast strain)

  • Isotype control antibodies (same isotype but different specificity)

  • Secondary antibody-only controls

  • Pre-immune serum controls

• Positive controls:

  • Tissues/cells known to express high levels of the target protein

  • Recombinant protein standards

  • Overexpression systems with tagged constructs

• Specificity controls:

  • Peptide competition experiments

  • Multiple antibodies targeting different epitopes

  • Cross-validation between different detection techniques

• Technical controls:

  • Loading controls for Western blots (e.g., Pgk1p)

  • Subcellular fraction markers (e.g., Cox3p for inner mitochondrial membrane, Porin for outer mitochondrial membrane, Dpm1p for ER, V-ATPase for vacuole)

  • Standardized recombinant protein dilution series for quantification

These controls ensure reliable interpretation of results and facilitate troubleshooting when unexpected findings occur.

How should samples be prepared for optimal detection of ISCA1/Isc1p in different experimental contexts?

Sample preparation is critical for successful detection of ISCA1/Isc1p:

For ISCA1 in mammalian systems:

• Cell/tissue lysis: Use buffers containing protease inhibitors to prevent degradation

• Mitochondrial isolation: Consider differential centrifugation methods optimized for mitochondria

• Protein extraction: Optimize detergent concentration for membrane protein solubilization

• Sample storage: Aliquot samples and store at -80°C to avoid freeze-thaw cycles

For Isc1p in yeast:

• Growth conditions: Culture cells to post-diauxic phase when Isc1p associates with mitochondria

• Mitochondrial purification: Use differential centrifugation followed by Nycodenz gradient ultracentrifugation for high purity

• Membrane fractionation: For submitochondrial localization, use osmotic swelling followed by protease protection assays

• Enzymatic activity measurement: Prepare samples under conditions that preserve enzymatic activity

For both proteins, consider:

• Fixation for immunofluorescence: Optimize fixation methods (paraformaldehyde, methanol) to preserve epitope accessibility

• Antigen retrieval: Test different methods if working with fixed tissues

• Blocking conditions: Optimize to reduce background while preserving specific signal

What statistical approaches are appropriate for analyzing ISCA1/Isc1p expression or activity data?

Statistical analysis of ISCA1/Isc1p data should be tailored to the experimental design:

• For comparing two groups (e.g., wild-type vs. knockout):

  • Student's unpaired t-test for normally distributed data

  • Mann-Whitney U test for non-parametric data

  • Sample size determination through power analysis

• For multiple group comparisons:

  • ANOVA followed by appropriate post-hoc tests

  • Correction for multiple comparisons (e.g., Bonferroni, Tukey)

• For time-course experiments:

  • Repeated measures ANOVA

  • Mixed-effects models for incomplete datasets

• For correlation analyses:

  • Pearson correlation for linear relationships

  • Spearman correlation for non-parametric relationships

• Data presentation:

  • Report means ± standard error of the mean (SEM) as used in published Isc1p research

  • Include individual data points when possible

  • Use appropriate scales and clearly labeled axes

Researchers should report exact p-values, sample sizes, and statistical tests used to facilitate reproducibility and meta-analysis.

How can researchers reconcile conflicting results in ISCA1/Isc1p research?

When faced with conflicting results:

• Examine methodological differences:

  • Different antibodies may have varying specificities or target different epitopes

  • Sample preparation protocols may affect protein detection

  • Experimental systems (cell lines, organisms) may yield different results

• Consider biological context:

  • Growth conditions: For Isc1p, localization depends on growth phase

  • Cell/tissue type: ISCA1 expression varies across tissues

  • Genetic background: Different strains may influence results

  • Post-translational modifications may affect antibody recognition

• Validation strategies:

  • Use multiple detection methods (Western blot, immunofluorescence, activity assays)

  • Collaborate with other laboratories to reproduce results

  • Perform systematic literature review and meta-analysis

• Transparency in reporting:

  • Document all experimental conditions in detail

  • Report negative results alongside positive findings

  • Consider pre-registration of study protocols

• Exploratory data analysis:

  • Look for patterns in conflicting data that might suggest underlying mechanisms

  • Consider whether discrepancies might reflect genuine biological heterogeneity

How can researchers distinguish between direct and indirect effects when studying ISCA1/Isc1p function?

Distinguishing direct from indirect effects requires mechanistic approaches:

• Temporal analysis:

  • Acute vs. chronic manipulations (e.g., inducible systems vs. stable knockouts)

  • Time-course experiments to identify primary vs. secondary effects

  • Pulse-chase experiments to track metabolic changes

• Rescue experiments:

  • Complementation with wild-type protein in knockout models

  • Structure-function analysis using mutants with specific deficiencies

  • Domain-specific manipulations

• Direct interaction studies:

  • In vitro reconstitution with purified components

  • Proximity labeling to identify molecules in immediate vicinity

  • Cross-linking to capture transient interactions

• Pathway analysis:

  • Epistasis experiments to determine order of action

  • Combined knockouts of multiple pathway components

  • Metabolomic profiling to trace metabolite flow

For Isc1p, studies comparing wild-type and isc1Δ mitochondria demonstrated a drastic reduction (93.1% loss) in α-hydroxylated phytoceramide levels, suggesting a direct role for Isc1p in generating these specific ceramide species in mitochondria .

What advanced analytical approaches can be applied to study ISCA1/Isc1p in complex biological samples?

Advanced analytical approaches include:

• Multi-omics integration:

  • Combine proteomics, transcriptomics, and metabolomics data

  • Network analysis to identify functional relationships

  • Machine learning approaches to identify patterns in complex datasets

• Advanced mass spectrometry:

  • Targeted proteomics (SRM/MRM) for precise quantification

  • Phosphoproteomics to identify regulatory modifications

  • Lipidomics to characterize sphingolipid profiles in Isc1p research

  • Cross-linking mass spectrometry to map protein interactions

• Live-cell imaging approaches:

  • FRET-based biosensors to monitor protein activity in real-time

  • Photoactivatable or photoswitchable fusion proteins for tracking

  • Correlative light and electron microscopy for ultrastructural context

• Single-cell analysis:

  • Single-cell proteomics to address cellular heterogeneity

  • Spatial transcriptomics to correlate expression with localization

  • High-content screening to analyze subcellular phenotypes

• Computational modeling:

  • Molecular dynamics simulations of protein-membrane interactions

  • Systems biology approaches to model pathway kinetics

  • Structure-based drug design for developing specific inhibitors

These advanced approaches can provide deeper insights into ISCA1/Isc1p function within complex biological systems and potentially reveal novel therapeutic targets for related disorders.

What are promising approaches for studying ISCA1's role in human mitochondrial disorders?

The association between ISCA1 and multiple mitochondrial dysfunctions syndrome suggests several research directions:

• Patient-derived models:

  • iPSC-derived cell lines from affected individuals

  • Organoid models to study tissue-specific effects

  • CRISPR-engineered cell lines with patient-specific mutations

• High-resolution structural studies:

  • Cryo-EM structures of ISCA1 in complex with interacting partners

  • Structural analysis of disease-associated mutants

  • Structure-guided design of stabilizing compounds

• In vivo models:

  • Conditional knockout mouse models to avoid embryonic lethality

  • Tissue-specific deletion to understand organ vulnerability

  • Rescue experiments with modified ISCA1 variants

• Biomarker development:

  • Identification of specific metabolites associated with ISCA1 dysfunction

  • Development of sensitive assays for early detection

  • Correlation of biomarkers with clinical progression

• Therapeutic approaches:

  • Small molecule screens for compounds that enhance residual ISCA1 function

  • Gene therapy approaches for ISCA1 replacement

  • Metabolic bypasses that circumvent defective iron-sulfur cluster assembly

These approaches could advance our understanding of ISCA1's role in disease and potentially lead to diagnostic tools or therapeutic interventions.